New MRI lung scanning method could change treatment for compromised lung function in transplant patients. Read on!

The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...

A meta-analysis found that peer reviews in radiation oncology led to recommendations to change treatment plans in more than ...

Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Although lung cancer survival is improving in the United States, 21% of patients with lung cancer did not receive treatment ...

Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...

Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...